PR is great for some, depressing for others;  all

PR is great for some, depressing for others;  all based on what you were expecting from the poster presentation.  Remember, we were told early in the year that the poster presentation would be very cut and dried with data only from the early cohorts and no ongoing data would be given.  We received just that.

What we did receive, though, was further confirmation of just where we stand in the trial (middle of cohort 4), the number of people still in the trial, the fact the trial data to date is pretty much same as the pre clinical data (this was the most important news for me and gives me confidence the balance of the trial will most likely follow in the same footsteps), and everyone connected with the trial is pleased with the progress to date.

I go back to our local experts  views that this being so important a trial that DF will not put out preliminary data but will most likely wait until they confirm results before putting out any news.  As such, I believe we are given little to no hard data til right about the end of the year.  I do hope that we will be kept abreast of cohort progression.

Maybe the Q/A throws us some new seeds of info, but even if it doesn't, we still might have some very meaningful back room conversations at ASCO between Dr M/Leo and a whole assortment of influential individuals in various areas important to CTIX.  I have to believe this is the main purpose of ASCO.

Regarding the PR, I did find it drab and not living up to the advance notice LE gave regarding it.  I would in no way call it a fluff PR as it spelled out progress and reaffirmed the trial is proceeding smoothly.  Just thought there would be a little more meat on this bone.